These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 26886466)
1. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia. Sible AM; Nawarskas JJ; Anderson JR Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466 [TBL] [Abstract][Full Text] [Related]
2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons. Yadav K; Sharma M; Ferdinand KC Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986 [TBL] [Abstract][Full Text] [Related]
3. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Blom DJ; Dent R; Castro RC; Toth PP Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264 [TBL] [Abstract][Full Text] [Related]
4. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management? Stein EA Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia. Paton DM Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592 [TBL] [Abstract][Full Text] [Related]
6. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders. Gupta S Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050 [TBL] [Abstract][Full Text] [Related]
7. Defining the Role of PCSK9 Inhibitors in the Treatment of Hyperlipidemia. Whayne TF Am J Cardiovasc Drugs; 2016 Apr; 16(2):83-92. PubMed ID: 26596726 [TBL] [Abstract][Full Text] [Related]
8. Evolocumab: A Review in Hyperlipidemia. Keating GM Am J Cardiovasc Drugs; 2016 Feb; 16(1):67-78. PubMed ID: 26643308 [TBL] [Abstract][Full Text] [Related]
9. [Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement]. Cybulska B; Gaciong Z; Hoffman P; Jankowski P; Kłosiewicz-Latoszek L; Kaźmierczak J; Mitręga K; Opolski G; Pająk A; Ponikowski P; Rynkiewicz A; Stępińska J; Średniawa B; Kalarus Z Kardiol Pol; 2016; 74(4):394-8. PubMed ID: 27098076 [TBL] [Abstract][Full Text] [Related]
10. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397 [TBL] [Abstract][Full Text] [Related]
15. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype? Hadjiphilippou S; Ray KK Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304 [TBL] [Abstract][Full Text] [Related]
16. New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Giunzioni I; Tavori H Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307 [TBL] [Abstract][Full Text] [Related]